These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 38469404)

  • 1. The combination use of inclisiran and statins versus statins alone in the treatment of dyslipidemia in mainland China: a cost-effectiveness analysis.
    Zhou W; Liang Z; Lou X; Wang N; Liu X; Li R; Pai P
    Front Pharmacol; 2024; 15():1283922. PubMed ID: 38469404
    [No Abstract]   [Full Text] [Related]  

  • 2. Inclisiran as Adjunct Lipid-Lowering Therapy for Patients with Cardiovascular Disease: A Cost-Effectiveness Analysis.
    Kam N; Perera K; Zomer E; Liew D; Ademi Z
    Pharmacoeconomics; 2020 Sep; 38(9):1007-1020. PubMed ID: 32789593
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost Effectiveness of Inclisiran in Atherosclerotic Cardiovascular Patients with Elevated Low-Density Lipoprotein Cholesterol Despite Statin Use: A Threshold Analysis.
    Desai NR; Campbell C; Electricwala B; Petrou M; Trueman D; Woodcock F; Cristino J
    Am J Cardiovasc Drugs; 2022 Sep; 22(5):545-556. PubMed ID: 35595929
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-Effectiveness of Evolocumab in Adult Patients with Atherosclerotic Cardiovascular Disease from Chinese Healthcare Perspective.
    Xie W; Song Y; Qin X; Jin P
    Adv Ther; 2023 Feb; 40(2):489-503. PubMed ID: 36371480
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term Cost-effectiveness of Statin Treatment for Primary Prevention of Cardiovascular Disease in the Elderly.
    Lin L; Teng M; Zhao YJ; Khoo AL; Seet RC; Yong QW; Yeo TC; Lim BP
    Cardiovasc Drugs Ther; 2015 Apr; 29(2):187-97. PubMed ID: 25860556
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness analysis of hemodialysis plus hemoperfusion versus hemodialysis alone in adult patients with end-stage renal disease in China.
    Wang H; Jin H; Cheng W; Qin X; Luo Y; Liu X; Fu Y; Jiang G; Lu W; Jin C; Pennington M
    Ann Transl Med; 2021 Jul; 9(14):1133. PubMed ID: 34430574
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-Effectiveness of Icosapent Ethyl, Evolocumab, Alirocumab, Ezetimibe, or Fenofibrate in Combination with Statins Compared to Statin Monotherapy.
    Michaeli DT; Michaeli JC; Boch T; Michaeli T
    Clin Drug Investig; 2022 Aug; 42(8):643-656. PubMed ID: 35819632
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-Effectiveness, Burden of Disease and Budget Impact of Inclisiran: Dynamic Cohort Modelling of a Real-World Population with Cardiovascular Disease.
    Galactionova K; Salari P; Mattli R; Rachamin Y; Meier R; Schwenkglenks M
    Pharmacoeconomics; 2022 Aug; 40(8):791-806. PubMed ID: 35723806
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Estimation of the value of curative therapies in oncology: a willingness-to-pay study in China.
    Huang L; Peng X; Sun L; Zhang D
    Cost Eff Resour Alloc; 2023 Jun; 21(1):37. PubMed ID: 37277820
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Results of a Markov model analysis to assess the cost-effectiveness of statin therapy for the primary prevention of cardiovascular disease in Korea: the Korean Individual-Microsimulation Model for Cardiovascular Health Interventions.
    Kang HY; Ko SK; Liew D
    Clin Ther; 2009 Dec; 31(12):2919-30; discussion 2916-8. PubMed ID: 20110032
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vericiguat for the Treatment of Heart Failure with Reduced Ejection Fraction Following a Worsening Heart Failure Event: A Cost-Effectiveness Analysis from the Perspective of Chinese Healthcare Providers.
    Yu X; Hao Y; Zhu Z; Zhang W; Liu B; Ma M; Zhang X; Wei N; Wang J; Liu F
    Clin Drug Investig; 2023 Apr; 43(4):241-250. PubMed ID: 36929485
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation.
    Main C; Bojke L; Griffin S; Norman G; Barbieri M; Mather L; Stark D; Palmer S; Riemsma R
    Health Technol Assess; 2006 Mar; 10(9):1-132. iii-iv. PubMed ID: 16545208
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A systematic review and economic evaluation of statins for the prevention of coronary events.
    Ward S; Lloyd Jones M; Pandor A; Holmes M; Ara R; Ryan A; Yeo W; Payne N
    Health Technol Assess; 2007 Apr; 11(14):1-160, iii-iv. PubMed ID: 17408535
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-Effectiveness Analysis of Adding Palbociclib as a Second-Line Endocrine Therapy for HR
    Zhang Y; Zeng X; Deng H; Ma F; Peng Y; Yi L; Tan C; Peng L
    Clin Ther; 2019 Jun; 41(6):1175-1185. PubMed ID: 31104762
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is Reconstruction of Unstable Midfoot Charcot Neuroarthropathy Cost Effective from a US Payer's Perspective?
    Albright RH; Joseph RM; Wukich DK; Armstrong DG; Fleischer AE
    Clin Orthop Relat Res; 2020 Dec; 478(12):2869-2888. PubMed ID: 32694315
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Methodology and results of cost-effectiveness of LDL-C lowering with evolocumab in patients with acute myocardial infarction in China.
    Wan Y; Liu J; Zhan X; Zhang Y; You R
    Cost Eff Resour Alloc; 2023 Dec; 21(1):93. PubMed ID: 38041072
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of Evolocumab and Ezetimibe, Both Combined with Statin Therapy, for Patients with Recent Acute Coronary Syndrome: A Cost-Effectiveness Analysis from the Chinese Healthcare Perspective.
    Xi X; Wang X; Xie W; Jia Y; Sanchez SZ; Martinez L; Zhao Q
    Cardiovasc Drugs Ther; 2023 Oct; 37(5):905-916. PubMed ID: 35467312
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Cost-effectiveness of community-based treatment of chronic hepatitis B in China].
    Zhang SX; Yang PC; Cai YL; Lin Y; Zou YH
    Zhonghua Liu Xing Bing Xue Za Zhi; 2017 Jul; 38(7):860-867. PubMed ID: 28738456
    [No Abstract]   [Full Text] [Related]  

  • 19. Effectiveness and cost-effectiveness of six GLP-1RAs for treatment of Chinese type 2 diabetes mellitus patients that inadequately controlled on metformin: a micro-simulation model.
    Yuan S; Wu Y
    Front Public Health; 2023; 11():1201818. PubMed ID: 37744474
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness analysis of fruquintinib versus regorafenib as the third-line therapy for metastatic colorectal cancer in China.
    Guan X; Li H; Xiong X; Peng C; Wang N; Ma X; Ma A
    J Med Econ; 2021; 24(1):339-344. PubMed ID: 33571036
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.